SCHEMBL22637706

SCHEMBL22637706

COC(C)(C)c1cc(-c2noc([C@H](C)N)n2)ccn1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KCNT1 Q5JUK3 10/20 0.55
▸ KCNQ1 P51787 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ CACNA1C Q13936 1/20 0.41
▸ SCN5A Q14524 1/20 0.41
▸ KCNMB1 Q16558 1/20 0.41
▸ KCNT2 Q6UVM3 1/20 0.41
▸ S1PR1 P21453 7/20 0.37
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ S1PR3 Q99500 2/20 0.36
▸ NPC1 O15118 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29463551 1.00 KCNT1 (0.55) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL22637708 1.00 KCNT1 (0.55) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL28710638 0.83 KCNT1 (0.56) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL22649328 0.83 KCNT1 (0.56) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL28713230 0.83 KCNT1 (0.56) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL28713228 0.83 KCNT1 (0.56) KCNT1KCNQ1KCNH2CACNA1CSCN5A
Hydrochloric Acid SCHEMBL28705235 0.82 KCNT1 (0.55) KCNT1KCNQ1KCNH2CACNA1CSCN5A
Hydrochloric Acid SCHEMBL28705236 0.82 KCNT1 (0.55) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL22637342 0.81 KCNT1 (0.68) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL22637347 0.81 KCNT1 (0.68) KCNT1KCNQ1KCNH2CACNA1CSCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220259193-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2022-08-18 — — US disclosed
CN-114269340-A KCNT1 inhibitors and methods of use 普拉克西斯精密药物股份有限公司 2022-04-01 — — CN disclosed
EP-3962481-A1 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2022-03-09 — — EP disclosed
WO-2020227101-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2020-11-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259193-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 KCNT1 1/4885KCNQ1 4/4885KCNH2 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback